This study’s findings suggest that acetylated LDL(+)ulex-lectin(+) cells, commonly referred to as EPCs, release potent proangiogenic growth factors. Their conclusion states: “These findings may allow for development of novel angiogenic therapies relying on secreted growth factors or on recruitment of endogenous monocytes/macrophages to sites of ischemia.”
